Investor Presentation
Second Quarter 2021 Financial Highlights
O
Record Quarterly Revenue - Strong Base, COVID tailwinds
ā $163M; +86% overall, +69% organic
I. BASE: 31 pts. of growth
II. COVID: 42 pts. of growth
III. M&A: 13 pts. of growth
Gross Margin and Operating Margin Expansion
o GAAP GM: 62% (from 57.9% Q2 '20)
o Adjusted GM: 62% (from 58.2% Q2 '20)
o GAAP Op. Margin: 29.6% (from 22.3% Q2 '20)
o Adjusted Op. Margin: 34.7% Adjusted (from 29.2% Q2 '20)
Net Income Per Share (EPS) Growth
o Fully diluted EPS: $0.64 GAAP (from $0.30 Q2 '20)
o Adjusted Fully diluted EPS $0.79 (from $0.42 Q2 '20)
M&A,
7%
$0.90
$0.80
$0.70
$0.60
$0.50
$0.40
$0.30
$0.20
$0.10
$0.00
BASE,
66%
$0.42
Q2 '20
RREPLIGEN
INSPIRING ADVANCES IN BIOPROCESSING
COVID,
27%
$0.79
Q2 '21
Q2 2021
Revenue
Composition
Q2 2021
Adj. EPS
20View entire presentation